echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > CHMP recommends approval of Benlysta for the treatment of active lupus nephritis

    CHMP recommends approval of Benlysta for the treatment of active lupus nephritis

    • Last Update: 2021-04-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The clinical manifestations of lupus nephritis include hematuria, nephrotic proteinuria, and azotemia in the advanced stage of the disease.


    diagnosis

    GlaxoSmithKline (GSK) today announced that the European Medicines Management Agency (EMA) adopted a positive person with opinions and Drug Committee (CHMP), recommended that Benlysta (belimumab) Joint immune suppression therapy for active lupus nephritis (LN ).


    Management Immunity

    The CHMP opinion is based on data from the BLISS-LN study.


    .


     

    Original source:

    Original source:

    href="" target="_blank" rel="noopener">leave a message here

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.